Rocket Lab Analysts Trim Price Targets While Keeping Their Buy Ratings — and the Gap Between the Two Tells the Story

When a Wall Street analyst cuts a price target but leaves the rating untouched, the headline usually focuses on the downgrade that didn't happen. At Rocket Lab, the more instructive signal runs the other way: the targets are coming down sharply, and the recommendations are staying put. That divergence — conviction intact, arithmetic revised — is where the real debate now sits.

Citizens analyst Trevor Walsh lowered his target to $90 from $130 on October 16, according to media reports, while keeping his outperform rating on the launch and space-systems company. A day earlier, KeyBanc's Michael Leshock cut his own target to $100 from $135 and maintained an overweight stance. Other revisions clustered across a range from $67 to $100, with neutral-to-positive ratings attached.

Read only the ratings and nothing appears to have changed. Read only the targets and the picture looks like a retreat. Neither reading holds up on its own. What the two houses have done is reprice the same optimistic thesis against a schedule that has moved.

The Tank Dome That Reset the Calendar

The trigger sits in the first stage of the Neutron rocket. Rocket Lab disclosed roughly a week before the analyst moves that the vehicle's debut flight would slip to 2027, after voids were found in the forward dome of the carbon-composite fuel tank. The company documented the revised timeline in a regulatory filing and said it had altered its manufacturing process; a replacement dome is to be built and tested.

That distinction matters for anyone weighing the equity. A new date describes a plan, not a milestone reached. Nothing in the announcement establishes that the underlying manufacturing defect has been solved — only that a fix is underway.

Needham's Ryan Koontz made the connection explicit on October 16. He reaffirmed his buy rating and his $120.00 target, but trimmed his revenue forecast for fiscal 2027 because of the Neutron delay. A lower sales estimate need not drag a price target down with it, yet the move shows the slip is already feeding into financial models. Not every analyst responded to the same development risk in the same way.

What the Tape Said, and What It Didn't

The stock's premarket move on the day ran to -3.8%, with a later reading of -3.3% showing continued pressure. Reuters reported after-hours losses when the manufacturing problem first surfaced about a week earlier. Neither data point pins the day's decline to a single cause, and the earlier delay should not be presented as the established driver of the current session. Price action confirms the mood; it doesn't explain it.

The harder question is whether upbeat ratings can hold once the revenue assumptions beneath them are being marked down. That is the tension investors are being asked to price: confidence can survive while its numerical foundation grows more conservative.

November 9 Is the Next Reckoning

Rocket Lab will report third-quarter 2026 results after the U.S. close on November 9, with a conference call to follow. The date offers a venue for clarity, not a guarantee of it. What counts is substance — concrete word on the development status and the reworked timeline — rather than the fact of the update itself.

Until then, the lowered targets carry more weight than the unchanged labels. Optimism is still on the table at Citizens, KeyBanc and Needham. It just has to be earned against demonstrable progress on the problem that pushed Neutron into 2027.